Free Trial

California Public Employees Retirement System Has $29.43 Million Holdings in DaVita Inc. (NYSE:DVA)

DaVita logo with Medical background

California Public Employees Retirement System raised its position in DaVita Inc. (NYSE:DVA - Free Report) by 75.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 196,788 shares of the company's stock after acquiring an additional 84,375 shares during the period. California Public Employees Retirement System owned about 0.24% of DaVita worth $29,430,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in DaVita in the fourth quarter worth about $41,000. Quarry LP bought a new stake in shares of DaVita in the 3rd quarter valued at approximately $60,000. Venturi Wealth Management LLC raised its holdings in shares of DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after buying an additional 152 shares in the last quarter. Versant Capital Management Inc boosted its stake in DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after buying an additional 169 shares in the last quarter. Finally, Blue Trust Inc. grew its position in DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after acquiring an additional 131 shares during the period. Institutional investors own 90.12% of the company's stock.

DaVita Price Performance

DVA traded down $2.98 during midday trading on Tuesday, hitting $143.63. The company had a trading volume of 904,702 shares, compared to its average volume of 816,972. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The firm's 50-day simple moving average is $153.98 and its 200-day simple moving average is $156.84. The company has a market capitalization of $11.49 billion, a PE ratio of 13.37, a P/E/G ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of analyst reports. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. StockNews.com lowered shares of DaVita from a "buy" rating to a "hold" rating in a research report on Wednesday, April 2nd. Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $166.33.

View Our Latest Research Report on DaVita

DaVita Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Should You Invest $1,000 in DaVita Right Now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Markets in Rally Mode: Will Earnings Keep It Going?
3 Tech Stocks to Buy Now—And 3 You’ll Regret Keeping
After Stellar Earnings, Is TSMC the Next Chip Leader?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines